title: Considerations in the development of an in vitro dissolution condition for lacidipine tablets: in vivo pharmacokinetic evaluation.
abstract: In this study, a new discriminative dissolution condition for lacidipine tablets was developed by the established in vitro-in vivo relationship. Series of dissolution media of phosphate buffer solution (PBS) covering the pH range of 1-7.2 and pH 6.8 PBS containing different concentrations of sodium dodecyl sulfate (SDS), were prepared and used to investigate the dissolution behavior of lacidipine tablets. There was an obvious difference in the dissolution profiles of the both brands in pH 6.8 PBS medium containing 0.1% SDS. The pharmacokinetic study of the two lacidipine tablets was carried out in the healthy beagle dogs at a single dose of 4 mg. Statistical comparison of the AUC(₀₋₂₄), C(max), and T(max) showed a significant difference in the two brand tablets, coinciding with the dissolution performance with pH 6.8 PBS containing 0.1% SDS. The superiority of the proposed system, pH 6.8 PBS containing 0.1% SDS, could serve as a dissolution medium for lacidipine tablets, and more important it could discriminate the in vivo pharmacokinetic behavior for different brands of products. In summary, in vivo pharmacokinetic evaluation is essential to develop an appropriate in vitro dissolution condition for oral solid dosage forms of poorly soluble drugs.
authors.affiliation: Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
authors.forename: Mingyu
authors.initials: M
authors.lastname: Sun
authors.forename: Jin
authors.initials: J
authors.lastname: Sun
authors.forename: Shuangfeng
authors.initials: S
authors.lastname: He
authors.forename: Yongjun
authors.initials: Y
authors.lastname: Wang
authors.forename: Yinghua
authors.initials: Y
authors.lastname: Sun
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Liu
authors.forename: Zhonggui
authors.initials: Z
authors.lastname: He
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics*; D001682:Biological Availability; D002021:Buffers; D002121:Calcium Channel Blockers / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics*; D002626:Chemistry, Pharmaceutical; D004095:Dihydropyridines / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics*; D004285:Dogs; D004355:Drug Stability; D006207:Half-Life; D006863:Hydrogen-Ion Concentration; D007408:Intestinal Absorption; D009994:Osmolar Concentration; D011897:Random Allocation; D015203:Reproducibility of Results; D012967:Sodium Dodecyl Sulfate / Q000737:chemistry; D012995:Solubility; D013501:Surface-Active Agents / Q000737:chemistry; D013607:Tablets; D013678:Technology, Pharmaceutical
chemical_list: D000959:Antihypertensive Agents; D002021:Buffers; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D013501:Surface-Active Agents; D013607:Tablets; C060285:lacidipine; D012967:Sodium Dodecyl Sulfate